12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD) [clinicaltrials:NCT00144196]

Bio2RDF identifier

NCT00144196

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00144196

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00144196

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:622caf56b633089ea886f65319748980

brief summary [clinicaltrials_vocabulary:brief-summary]

To show that treatment ...... ording to Swedish guidelines.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

12 Week Efficacy of Tiotropium ...... Swedish Guidelines (SPIRIMILD)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:929b08f11e43827c9a7d3d2a023da9ac]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:09b4e143e669496e04373efe698e7603]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:1c41e532bc679ddee32d2459c123b550]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:20dcd57e5a20ee7e9bd2d11c49ddc082]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:441acc791dcc534cee2a517f1bc567a3]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:47ab765c92341263f91319b6f91094c5]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:6476c574faa15fac4060708bd8aca10d]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:6ac0c2c0391a8dfb2a9d2fd27eb2b429]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:6c0c1a620c561d1dc24d18c2f13582b3]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:80a4e066dc92cf054ae291353de4c623]

The primary efficacy endpoint is defined as area under the curve of change in FEV1 from baseline for the time period from pre-dose to 2 hours post dose (AUC0 2hFEV1) after 12 weeks of randomised treatment. week 12 [clinicaltrials_resource:827f6053a634dbe982281fb36aac252a]

completion date [clinicaltrials_vocabulary:completion-date]

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Following an initial sc ...... o. Randomisation is 1:1

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00144196 [clinicaltrials_resource:836d411660bd466c00f9c2900b20c74a]

enrollment [clinicaltrials_vocabulary:enrollment]

224

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2005-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

tiotropium (Spiriva) [clinicaltrials_resource:bcb6376286b35abbe04ab36fc2be4288]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Tiotropium [clinicaltrials_resource:17b37513b438cefbf8247a55601652f1]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

link [clinicaltrials_vocabulary:link]

[clinicaltrials_resource:2095047f1d14b0e3a3de155ae7ffb09f]

[clinicaltrials_resource:36294589b2974e462c84962942916a53]

location [clinicaltrials_vocabulary:location]

Boehringer Ingelheim Investigational Site [clinicaltrials_resource:0734ed94d0223f274871b8cf8d422458]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00144196

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A 12-week Double-blind, Random ...... Swedish Guidelines (SPIRIMILD)

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

2,05281005859375e+2

http://www.w3.org/2001/XMLSchema#float

overall official [clinicaltrials_vocabulary:overall-official]

Boehringer Ingelheim Study Coordinator [clinicaltrials_resource:23b157b69e3d05c37ac9eb88c53a597c]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Sweden: Medical Products Agency [clinicaltrials_resource:7c21b30b49d2d7f3e344daca0730fae9]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

source [clinicaltrials_vocabulary:source]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

start date [clinicaltrials_vocabulary:start-date]

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00144196 study design [clinicaltrials_resource:21a8c0ee7bdb2003885a0418ef8fe1fd]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00144196

verification date [clinicaltrials_vocabulary:verification-date]

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00144196

http://www.w3.org/2001/XMLSchema#string

title

12 Week Efficacy of Tiotropium ...... Swedish Guidelines (SPIRIMILD)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

12 Week Efficacy of Tiotropium ...... ) [clinicaltrials:NCT00144196]

@en